NeosMany of the best bargain stocks of the past two years have hit the mainstream, but there’s still plenty of promising companies to find at the entry-point of the market. Innovative pharmaceuticals offer high potential for growth with low stock prices on some of the best companies. Neos Therapeutics Inc. (NASDAQ: NEOS) is one option to consider.

Neos is the developer of a proprietary modified-release drug platform that allows for the slow release of medication. The company has already received FDA approval for its platform and three of its amphetamine and methylphenidate drugs used for the treatment of ADHD. Slow-release stimulants are particularly effective for ADHD as they help to balance the brain chemistry of patients and allow them to focus and lead normal lives. Beyond the company’s drugs, the modified release platform could be licensed to competitors.

With a bargain stock and an expected upside with a target price of $1, this is one of the best penny picks to consider today. It could fit well into any alternative portfolio that is built around low-cost stocks with upside potential. There’s also momentum in this stock, suggesting it could go even higher than the target price in the coming weeks.

Key Data:

  • 1 Year Price Growth: -47.56%
  • YTD Price Growth: 42%
  • 3 Month Price Growth: 56%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.